文献速递浆细胞疾病

基于Connect® MM患者登记系统的新诊断多发性骨髓瘤总生存预后模型开发

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry.
PubMed 文献 · Br J Haematol · 2019-08-05

利用美国多中心前瞻性观察队列Connect® MM登记系统(3011例新诊断多发性骨髓瘤患者),在队列1(n=1493)中通过多变量分析识别与总生存相关的基线因素,并构建3年和5年生存矩阵。该工具可能有助于在 triplet 治疗时代评估新诊断多发性骨髓瘤患者的个体化结局。

要点

  • 该预后工具可生成3年和5年生存矩阵,辅助个体化预后评估。

核心结论

  • 基于Connect® MM登记系统开发的新诊断多发性骨髓瘤总生存预后模型,在内部和外部验证中显示出一定的区分度,可能有助于个体化预后评估。

研究设计与样本

  • 美国多中心前瞻性观察队列研究Connect® MM登记系统,纳入3011例新诊断多发性骨髓瘤患者,分为队列1(2009-2011年)和队列2(2012-2016年)。
  • 在队列1(n=1493)中通过多变量分析基线特征识别预后变量,并构建3年和5年生存矩阵。
  • 模型在队列2、MM-015和III期FIRST试验中进行内部和外部验证。

临床怎么用

  • 该预后工具可用于新诊断多发性骨髓瘤患者,结合基线特征生成3年和5年生存矩阵,辅助临床预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect® MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009-2011; Cohort 2: 2012-2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Terebelo HR, Abonour R, Gasparetto CJ, et al. Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. Br J Haematol. 2019. PMID: 31382320. doi:10.1111/bjh.16139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。